Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 20:15:1341632.
doi: 10.3389/fimmu.2024.1341632. eCollection 2024.

Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses

Yaxin Zhang  1   2 , Guan Jiang  2
Affiliations
Review

Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses

Yaxin Zhang et al. Front Immunol. .

Abstract

Biologics play a positive and effective role in the treatment of immune-related dermatoses. However, many other immune-related diseases have also manifested along with biologics treatment. Paradoxical reaction through immune-related dermatoses refer to the new onset or exacerbation of other immune-mediated dermatoses (mainly psoriasis and atopic dermatitis) after biologics treatment of inflammatory dermatoses (mainly psoriasis and atopic dermatitis), such as new atopic dermatitis (AD) in psoriasis (PsO) treatment and new PsO in AD treatment. A common genetic background and Inflammatory pathway are possible pathogenesis. Faced with paradoxical reactions, the choice of therapy needs to be directed toward therapies effective for both diseases, such as Janus kinase (JAK) inhibitors. The Janus kinase and signal transducer and activator of transcription (JAK-STAT) pathway plays an important role in the inflammatory pathway, and has been widely used in the treatment of AD and PsO in recent years. This article focuses on JAK inhibitors such as tofacitinib, baricitinib, ruxolitinib, Abrocitinib, upadacitinib, and deucravacitinib, to explore the possible application in treatment of paradoxical reactions. Common side effects, baseline risk factors and safety use of JAK inhibitors were discussed.

Keywords: JAK inhibitors; atopic dermatitis; immune-related dermatoses; paradoxical reaction; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Relationships of T cell polarization and cytokines of AD and PSO on the immune axis. AD is Th22 and Th2 polarized while PsO is Th17 and Th1 polarized. However, AD in Asian populations have both the characteristics of PsO and AD in European and American populations, where Th2, Th17, and Th22 are all activated.
Figure 2
Figure 2
JAK inhibitors target specific JAK kinases to inhibit skin disease-related cytokine downstream signaling pathways. Different cytokines are involved in the pathological processes of different diseases through signals mediated by specific JAK kinases. JAK inhibitors can be used as a therapeutic strategy for cytokine-related diseases by inhibiting specific JAK kinase activity. HS, Hidradenitis suppurativa; SLE, Systemic lupus erythematosus; CLE, Cutaneous lupus erythematosus; AD, Atopic dermatitis; SS, Sjögren’s syndrome.
See this image and copyright information in PMC

References

    1. Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. J Am Acad Dermatol (2022) 86(5):1080–91. doi: 10.1016/j.jaad.2020.12.010 - DOI - PubMed
    1. Munera-Campos M, Ballesca F, Richarz N, Ferrandiz C, Carrascosa JM. Paradoxical eczematous reaction to ixekizumab. J Eur Acad Dermatol Venereol (2019) 33(1):e40–e2. doi: 10.1111/jdv.15156 - DOI - PubMed
    1. Burlando M, Cozzani E, Russo R, Parodi A. Atopic-like dermatitis after secukinumab injection: A case report. Dermatol Ther (2019) 32(1):e12751. doi: 10.1111/dth.12751 - DOI - PubMed
    1. Messina F, Piaserico S. The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition. J Dermatolog Treat (2022) 33(5):2443–54. doi: 10.1080/09546634.2022.2062281 - DOI - PubMed
    1. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med (2015) 66:311–28. doi: 10.1146/annurev-med-051113-024537 - DOI - PMC - PubMed